Background: Programmed death mediator 2 (PD-L2), also called B7-DC and CD273, belongs to the B7 family of proteins, including B7-1, B7-2, B7-H2, B7-H1 (PD-L1). ) and B7 – H3. PD-L2 is a type I membrane protein and structurally consists of an extracellular domain containing one V-like and one C-like Ig domain, a transmembrane region, and a short cytoplasmic domain. PD-L2 is expressed on antigen-presenting cells, placental endothelium, and thymic nucleus and can be induced by LPS on B cells, INF, and gamma; in monocytes or LPS plus IFN and gamma; in dendritic cells. The CD28 and B7 protein families are critical regulators of the immune response. PD-L2 and PD-L1 are two ligands for PD-1, a member of the CD28/CTLA4 family, which is expressed on activated lymphoid cells, thus signaling to regulate T-cell activation and immune tolerance. The B7-DC/PD-1 interaction showed 2- to 6-fold higher affinity than the B7-H1/PD-1 interaction.The KRIBIOLISA Inhibitor Assay Kits available enable researchers to test the inhibitory effects of various compounds on specific enzymes at a higher output. These assays can help identify or characterize enzyme inhibitors, which is important in early drug discovery and development. They can also be useful in characterizing enzyme activity. These Inhibitor assay kits contain a known inhibitor as a control.
This Assay kit is designed to facilitate the identification and characterization of PD-L2 pathway inhibitors.
Assay Features include:
– Ready to use protocol with pre-coated breakapart wells for ease of use
– Standardisation and High Reproducibility
– Lot to Lot Consistency
– Accuracy and Precision
Validated against seven points for a Gold Ring Standard Quality – the benchmark sign for Krishgen quality.
The kits are used for assessing the specific biomarker in samples analyte which may be serum, plasma, biological fluids and cell culture supernatant.
Unlike competitor assays available, we offer pre-coated ready-to-use assays to ensure high level of reproducibility and accuracy.